Patents for A61P 35 - Antineoplastic agents (221,099)
02/1999
02/18/1999WO1999007394A1 Use of herpes vectors for tumor therapy
02/18/1999WO1999007386A1 Composition and method of treating cancer with tannic acid and tannin complexes
02/18/1999WO1999007383A1 Composition and method for regulating cell proliferation and cell death
02/18/1999WO1999007377A1 1-[4-(substituted alkoxy)benzyl]naphthalene compounds having estrogen inhibitory activity
02/18/1999WO1999007324A2 Conjugates targeted to the interleukin-2 receptor
02/18/1999WO1998029108A3 Compositions and methods for restoring a normal pattern of imprinting to cells
02/18/1999WO1998014593A3 Human telomerase catalytic subunit
02/18/1999CA2300977A1 Neutral sphingomyelinase
02/18/1999CA2299630A1 Compositions that specifically bind to colorectal cancer cells and methods of using the same
02/18/1999CA2299608A1 New epothilone derivatives, method for producing same and their pharmaceutical use
02/18/1999CA2299368A1 Conjugates targeted to the interleukin-2 receptor
02/18/1999CA2299322A1 Composition and method of treating cancer with tannic acid and tannin complexes
02/18/1999CA2299309A1 Benzothiophenes
02/18/1999CA2299269A1 Macrolides with antitumor activity
02/18/1999CA2298932A1 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
02/18/1999CA2298849A1 Lipoprotein-regulating medicaments
02/18/1999CA2298651A1 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
02/18/1999CA2298451A1 Secreted proteins and polynucleotides encoding them
02/18/1999CA2297967A1 Purine inhibitor of protein kinases, g proteins and polymerases
02/18/1999CA2274302A1 Lsr receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications
02/18/1999CA2245041A1 Optical active 1,4-dihydropyridine compounds as bradykinin antagonists
02/17/1999EP0897001A1 Polypeptide having a GTPase regulator activity, nucleic acids coding therefore and their use in diagnostics and therapy
02/17/1999EP0896626A1 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
02/17/1999EP0896625A2 Recombinant ribonuclease proteins
02/17/1999EP0896622A1 Chemokine alpha 2
02/17/1999EP0896586A1 ErbB3 ANTIBODIES
02/17/1999EP0896584A2 BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT HF-COLL-18/514cf) FOR INHIBITING THE GROWTH OF TUMOURS AND CAPILLARY PROFILERATIONS
02/17/1999EP0896582A1 Non-dendritic backbone peptide carrier
02/17/1999EP0896577A1 Taxane derivatives having a pyridil substituted c13 side chain, their preparation and their use as anti-tumor agents
02/17/1999EP0896544A1 Combination of a somatostatin analogue and a rapamycin
02/17/1999EP0896543A1 Drug for the treatment of tumours
02/17/1999EP0896537A1 Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
02/17/1999EP0633774B1 Topical administration of toremifene and its metabolites
02/17/1999CN1208413A Antagonists of gonadotropin releasing hormone
02/17/1999CN1208412A Antagonists of gonadotropin releasing hormone
02/17/1999CN1208409A Novel benzoyl guanidine derivatives process for their preparation and their use in the preparation of medicines
02/17/1999CN1208034A Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
02/17/1999CN1207946A Thioether conjugates
02/17/1999CN1207940A Anticancer medicine and its preparation
02/17/1999CN1207917A Application of theachrome in preparing potentiate and antidote for radiotherapy and chemotherapy medicine
02/17/1999CN1207909A Oral liquid for curing cancer
02/16/1999US5872242 Antisense oligonucleotide inhibition of ras
02/16/1999US5872226 Fibroblast growth factor homologous factor-1 (FHF-1)
02/16/1999US5872223 Immunoconjugates comprising tyrosine kinase inhibitors
02/16/1999US5872152 Use of MMP inhibitors
02/16/1999US5872146 Metalloproteinases involved in connective tissue breakdown, such as collagenase, stromelysin and gelatinase and tumor necrosis factor
02/16/1999US5872142 1,3-dioxane or -dioxolane derivatives of 1h-1,2,4-triazole
02/16/1999US5872140 Vitamin D analogues
02/16/1999US5872129 Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents
02/16/1999US5872107 Anticarcinogenic agents capture therapy for tumors
02/16/1999US5872106 Antimessenger oligonucleotide against urokinase receptor
02/16/1999US5872007 CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer
02/16/1999US5871998 Gene expression in transformed eukaryotic host cell; genetic engineering
02/16/1999US5871973 Cell division regulators
02/16/1999US5871968 P21WAF1 derivatives and diagnostic methods
02/16/1999US5871954 Acylation of peptide or protein by reacting with coenzyme a ester of an oxy- or thio-substituted fatty acid analog in presence of n-myristoyl transferase
02/16/1999US5871779 Treatment of arthropathies with vanadate compounds or analogues thereof
02/16/1999US5871727 Targeted adenovirus vectors
02/16/1999CA2000913C Family of high affinity antibodies for cancer treatment
02/15/1999CA2224096A1 The g-protein coupled receptor hfia041
02/14/1999CA2239264A1 Novel uses
02/13/1999CA2244797A1 Droloxifene for prevention of breast cancer
02/13/1999CA2240623A1 Novel rata
02/12/1999CA2239835A1 Human sdr2 cdna clone
02/11/1999WO1999006572A1 Synaptojanin isoform
02/11/1999WO1999006544A1 Membrane-bound cytokine compositions and methods of modulating an immune response using same
02/11/1999WO1999006540A2 Inhibitors of cell-cycle progression and uses related thereto
02/11/1999WO1999006435A1 Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
02/11/1999WO1999006434A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
02/11/1999WO1999006433A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
02/11/1999WO1999006431A1 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
02/11/1999WO1999006423A1 83 human secreted proteins
02/11/1999WO1999006397A2 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
02/11/1999WO1999006393A1 Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them
02/11/1999WO1999006391A1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof
02/11/1999WO1999006390A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4
02/11/1999WO1999006387A2 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
02/11/1999WO1999006372A1 Bis-acridinecarboxamides having antitumor activity
02/11/1999WO1999006361A2 N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
02/11/1999WO1999006340A2 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
02/11/1999WO1999006114A2 Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases
02/11/1999WO1999006057A1 Soya extract, process for its preparation and pharmaceutical composition
02/11/1999WO1999006055A1 Polynucleotide compositions
02/11/1999WO1999006053A1 N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
02/11/1999WO1999006041A1 SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS
02/11/1999WO1999006027A1 Pellet-type formulation intended for treating the intestinal tract
02/11/1999WO1998050397A3 Chimeric oligonucleotides and the use thereof
02/11/1999WO1998049311A3 Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
02/11/1999DE19728737C1 Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten A method for the detection and determination of GnRH receptors and the use of GnRH agonists and GnRH-antagonists for the treatment of a tumor originating in the brain and / or nervous system and / or the meninges
02/11/1999CA2299045A1 Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them
02/11/1999CA2298852A1 83 human secreted proteins
02/11/1999CA2298617A1 Acyclic metalloprotease inhibitors
02/11/1999CA2298573A1 Synaptojanin isoform
02/11/1999CA2298115A1 Inhibitors of cell-cycle progression and uses related thereto
02/11/1999CA2297894A1 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
02/11/1999CA2297747A1 Membrane-bound cytokine compositions and methods of modulating an immune response using same
02/11/1999CA2296485A1 N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
02/11/1999CA2296476A1 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
02/11/1999CA2295295A1 Substituted alkanohydroxamic acids and method of reducing tnf.alpha. levels
02/11/1999CA2291475A1 Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4